CJC1295 (WITH DAC)

Description

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide classified as a growth hormone-releasing hormone (GHRH) analog. It is a 30-amino acid chain that has been structurally modified to increase stability and extend its duration of activity compared to native GHRH fragments. The key distinction lies in the addition of the DAC component, which binds to plasma proteins such as albumin, thereby significantly prolonging the peptide’s half-life in circulation.

This extended half-life makes CJC-1295 with DAC an important tool in research focused on sustained peptide activity, pharmacokinetics, and receptor binding interactions. Researchers study its role in modulating growth hormone release dynamics and its ability to maintain consistent activity over time. Investigations also explore how the DAC modification influences systemic distribution and clearance rates compared to non-DAC versions.

CJC-1295 with DAC is strictly intended for laboratory and experimental use, providing a valuable model for understanding peptide design, extended-release mechanisms, and protein-binding strategies in peptide engineering.